Is GlaxoSmithKline Pharmaceuticals Ltd halal to invest in?

As of July 2026, GlaxoSmithKline Pharmaceuticals Ltd 500660.BO is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is GlaxoSmithKline Pharmaceuticals Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes GlaxoSmithKline Pharmaceuticals Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of GlaxoSmithKline Pharmaceuticals Ltd?

Muslim investors may consider investing in GlaxoSmithKline Pharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is GlaxoSmithKline Pharmaceuticals Ltd classified as HALAL?

Musaffa determines the Shariah status of GlaxoSmithKline Pharmaceuticals Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for GlaxoSmithKline Pharmaceuticals Ltd updated?

The Shariah compliance status of GlaxoSmithKline Pharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like GlaxoSmithKline Pharmaceuticals Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of GlaxoSmithKline Pharmaceuticals Ltd?

You can check the latest Shariah compliance status of GlaxoSmithKline Pharmaceuticals Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

GlaxoSmithKline Pharmaceuticals Ltd 500660.BO

Last Updated: Jul 17, 12:00 AM·BSE

500660.BO Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, GlaxoSmithKline Pharmaceuticals Ltd is classified as halal.

HALAL

Report Source: 2026 Annual Report

GlaxoSmithKline Pharmaceuticals Ltd. Stock Analysis 500660.BO

India Health Care Mid Cap Report: 2026 Annual

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 3,113 full-time employees. The firm is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The firm has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The firm's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The firm's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.

Key Statistics of GlaxoSmithKline Pharmaceuticals Ltd (500660.BO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹2,431.00₹2,509.90

Today's Open

₹2,492.45

Volume

3304.00

P/E Ratio (TTM)

40.99

Financial Metrics & Statements of GlaxoSmithKline Pharmaceuticals Ltd (500660.BO)

Super Investors Invested in GlaxoSmithKline Pharmaceuticals Ltd (500660.BO)

FAQ's for GlaxoSmithKline Pharmaceuticals Ltd (500660.BO)

As of July 2026, GlaxoSmithKline Pharmaceuticals Ltd 500660.BO is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes GlaxoSmithKline Pharmaceuticals Ltd using these criteria to determine its compliance status.
Muslim investors may consider investing in GlaxoSmithKline Pharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of GlaxoSmithKline Pharmaceuticals Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of GlaxoSmithKline Pharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of GlaxoSmithKline Pharmaceuticals Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.